Corvus Pharmaceuticals, Inc. financial data

Symbol
CRVS on Nasdaq
Location
863 Mitten Road, Suite 102, Burlingame, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 4, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 396 % +105%
Debt-to-equity 27.5 % -49.1%
Return On Equity -25.8 % +84.6%
Return On Assets -20.2 % +81.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 74.7M shares +16.2%
Common Stock, Shares, Outstanding 74.7M shares +19.3%
Entity Public Float 69M USD -18.1%
Common Stock, Value, Issued 7K USD +16.7%
Weighted Average Number of Shares Outstanding, Basic 82.8M shares +24.2%
Weighted Average Number of Shares Outstanding, Diluted 82.8M shares +24.2%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 29.8M USD +70.9%
General and Administrative Expense 9.11M USD +18.5%
Operating Income (Loss) -38.9M USD -54.9%
Nonoperating Income (Expense) 415K USD
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -15.1M USD +73.5%
Earnings Per Share, Basic 0 USD/shares +73.9%
Earnings Per Share, Diluted 0 USD/shares +37%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 2.87M USD -38.7%
Cash, Cash Equivalents, and Short-term Investments 65.7M USD +57.6%
Accounts Receivable, after Allowance for Credit Loss, Current 32K USD -54.3%
Other Assets, Current 509K USD -19.6%
Assets, Current 66.9M USD +56%
Property, Plant and Equipment, Net 221K USD +29.2%
Operating Lease, Right-of-Use Asset 927K USD +226%
Other Assets, Noncurrent 852K USD +238%
Assets 80.5M USD +36.8%
Accounts Payable, Current 1.97M USD +5.39%
Employee-related Liabilities, Current 610K USD -18.8%
Accrued Liabilities, Current 5.72M USD
Liabilities, Current 8.07M USD -82.6%
Operating Lease, Liability, Noncurrent 632K USD
Liabilities 8.71M USD -81.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax -1.06M USD -43.6%
Retained Earnings (Accumulated Deficit) -400M USD -3.92%
Stockholders' Equity Attributable to Parent 71.8M USD +478%
Liabilities and Equity 80.5M USD +36.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -8.26M USD -60.2%
Net Cash Provided by (Used in) Financing Activities 279K USD
Net Cash Provided by (Used in) Investing Activities 4.24M USD
Common Stock, Shares Authorized 290M shares 0%
Common Stock, Shares, Issued 74.7M shares +19.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -3.74M USD +27.6%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 2.87M USD -38.7%
Deferred Tax Assets, Valuation Allowance 90.5M USD +9.11%
Deferred Tax Assets, Gross 90.9M USD +9.11%
Operating Lease, Liability 354K USD
Payments to Acquire Property, Plant, and Equipment 36K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -15.4M USD +72.6%
Lessee, Operating Lease, Liability, to be Paid 358K USD
Property, Plant and Equipment, Gross 2.84M USD -40.7%
Operating Lease, Liability, Current 379K USD +7.06%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.43M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure +50%
Deferred Tax Assets, Operating Loss Carryforwards 64.1M USD +8.04%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Operating Lease, Payments 157K USD -66.8%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 22K USD -4.35%
Share-based Payment Arrangement, Expense 4.57M USD +65.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%